A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
NCT06859268 on ClinicalTrials.gov · last registry update 2026-03-03
Closed to new participants; the 643 already enrolled are still being followed. Due to report April 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Percent Change from Baseline in Body Weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. retatrutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P3
- Drug
- retatrutide
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 643
- Started
- 2025-03-05
- Primary completion
- 2028-04 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percent Change from Baseline in Body Weight
Conditions studied
Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the retatrutide page for this molecule’s full trial and approval history.